| 2-HYDROXY-1,4-NAPHTHOQUINONE | The risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nitrendipine. | Experimental |
| 2-mercaptobenzothiazole | The risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nitrendipine. | Vet Approved |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nitrendipine. | Experimental |
| Acebutolol | The serum concentration of Acebutolol can be increased when it is combined with Nitrendipine. | Approved |
| Acetaminophen | The serum concentration of Acetaminophen can be increased when it is combined with Nitrendipine. | Approved |
| Acetazolamide | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Acetazolamide. | Approved, Vet Approved |
| Acetylsalicylic acid | The serum concentration of Acetylsalicylic acid can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Nitrendipine. | Approved |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitrendipine. | Approved |
| Aldosterone | The serum concentration of Aldosterone can be increased when it is combined with Nitrendipine. | Experimental |
| Alfuzosin | Alfuzosin may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Aliskiren | Nitrendipine may increase the hypotensive activities of Aliskiren. | Approved, Investigational |
| Alitretinoin | The serum concentration of Alitretinoin can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Alprenolol | Alprenolol may increase the hypotensive activities of Nitrendipine. | Approved, Withdrawn |
| Ambrisentan | The serum concentration of Ambrisentan can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Amifostine | Nitrendipine may increase the hypotensive activities of Amifostine. | Approved, Investigational |
| Amiloride | The risk or severity of adverse effects can be increased when Amiloride is combined with Nitrendipine. | Approved |
| Amiodarone | The metabolism of Nitrendipine can be decreased when combined with Amiodarone. | Approved, Investigational |
| Amitriptyline | The serum concentration of Amitriptyline can be increased when it is combined with Nitrendipine. | Approved |
| Amlodipine | Amlodipine may increase the hypotensive activities of Nitrendipine. | Approved |
| Amobarbital | The metabolism of Nitrendipine can be increased when combined with Amobarbital. | Approved, Illicit |
| Amorolfine | The risk or severity of adverse effects can be increased when Amorolfine is combined with Nitrendipine. | Approved |
| Amphotericin B | The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine. | Approved, Investigational |
| Amyl Nitrite | The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Nitrendipine. | Approved |
| Anidulafungin | The risk or severity of adverse effects can be increased when Anidulafungin is combined with Nitrendipine. | Approved, Investigational |
| Apixaban | The serum concentration of Apixaban can be increased when it is combined with Nitrendipine. | Approved |
| Apomorphine | The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine. | Approved, Investigational |
| Apraclonidine | The risk or severity of adverse effects can be increased when Apraclonidine is combined with Nitrendipine. | Approved |
| Aprepitant | The serum concentration of Nitrendipine can be increased when it is combined with Aprepitant. | Approved, Investigational |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Arotinolol | The risk or severity of adverse effects can be increased when Arotinolol is combined with Nitrendipine. | Approved |
| Arsenic trioxide | The serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Artemether | The risk or severity of adverse effects can be increased when Artemether is combined with Nitrendipine. | Approved |
| Atazanavir | The metabolism of Nitrendipine can be decreased when combined with Atazanavir. | Approved, Investigational |
| Atenolol | The serum concentration of Atenolol can be increased when it is combined with Nitrendipine. | Approved |
| Atomoxetine | The metabolism of Nitrendipine can be decreased when combined with Atomoxetine. | Approved |
| Atosiban | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Atosiban. | Approved |
| Atracurium besylate | Nitrendipine may increase the neuromuscular blocking activities of Atracurium besylate. | Approved |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nitrendipine. | Approved |
| Bafilomycin A1 | The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nitrendipine. | Experimental |
| Barbexaclone | Barbexaclone may increase the hypotensive activities of Nitrendipine. | Experimental |
| Barbital | The metabolism of Nitrendipine can be increased when combined with Barbital. | Illicit |
| Barnidipine | The risk or severity of adverse effects can be increased when Barnidipine is combined with Nitrendipine. | Approved |
| Benazepril | Benazepril may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Bendroflumethiazide | Bendroflumethiazide may increase the hypotensive activities of Nitrendipine. | Approved |
| Benmoxin | Benmoxin may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Benzoic Acid | The risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nitrendipine. | Approved |
| Bepridil | Nitrendipine may increase the hypotensive activities of Bepridil. | Approved, Withdrawn |
| Betamethasone | The serum concentration of Betamethasone can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Betaxolol | Betaxolol may increase the hypotensive activities of Nitrendipine. | Approved |
| Bethanidine | Bethanidine may increase the hypotensive activities of Nitrendipine. | Approved |
| Bexarotene | The serum concentration of Nitrendipine can be decreased when it is combined with Bexarotene. | Approved, Investigational |
| Bifonazole | The risk or severity of adverse effects can be increased when Bifonazole is combined with Nitrendipine. | Approved |
| Bimatoprost | Bimatoprost may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Bisoprolol | Bisoprolol may increase the hypotensive activities of Nitrendipine. | Approved |
| Boceprevir | The metabolism of Nitrendipine can be decreased when combined with Boceprevir. | Withdrawn |
| Bortezomib | The metabolism of Nitrendipine can be decreased when combined with Bortezomib. | Approved, Investigational |
| Bosentan | The serum concentration of Nitrendipine can be decreased when it is combined with Bosentan. | Approved, Investigational |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Nitrendipine. | Approved |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine. | Approved |
| Bretylium | Nitrendipine may increase the hypotensive activities of Bretylium. | Approved |
| Brimonidine | Brimonidine may increase the hypotensive activities of Nitrendipine. | Approved |
| Brimonidine | Brimonidine may increase the antihypertensive activities of Nitrendipine. | Approved |
| Bromocriptine | The serum concentration of Bromocriptine can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Bucindolol | Bucindolol may increase the hypotensive activities of Nitrendipine. | Investigational |
| Bumetanide | The risk or severity of adverse effects can be increased when Bumetanide is combined with Nitrendipine. | Approved |
| Bupivacaine | The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine. | Approved, Investigational |
| Bupranolol | Nitrendipine may increase the hypotensive activities of Bupranolol. | Approved |
| Butenafine | The risk or severity of adverse effects can be increased when Butenafine is combined with Nitrendipine. | Approved |
| Butoconazole | The risk or severity of adverse effects can be increased when Butoconazole is combined with Nitrendipine. | Approved |
| Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Nitrendipine. | Approved |
| Caffeine | The serum concentration of Caffeine can be increased when it is combined with Nitrendipine. | Approved |
| Calcium | The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium. | Nutraceutical |
| Calcium Acetate | The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate. | Approved |
| Calcium Carbonate | The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium carbonate. | Approved |
| Calcium Chloride | The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Chloride. | Approved |
| Calcium Citrate | The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium citrate. | Approved |
| Calcium glubionate | The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate. | Approved |
| Calcium Gluceptate | The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate. | Approved |
| Calcium gluconate | The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate. | Approved, Vet Approved |
| Camptothecin | The serum concentration of Camptothecin can be increased when it is combined with Nitrendipine. | Experimental |
| Canagliflozin | The serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine. | Approved |
| Candesartan | Candesartan may increase the hypotensive activities of Nitrendipine. | Approved |
| Candicidin | The risk or severity of adverse effects can be increased when Candicidin is combined with Nitrendipine. | Withdrawn |
| Candoxatril | Candoxatril may increase the hypotensive activities of Nitrendipine. | Experimental |
| Capric acid | The risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nitrendipine. | Experimental |
| Captopril | Nitrendipine may increase the hypotensive activities of Captopril. | Approved |
| Carbamazepine | The metabolism of Nitrendipine can be increased when combined with Carbamazepine. | Approved, Investigational |
| Carbetocin | The risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine. | Approved |
| Carbomycin | The metabolism of Nitrendipine can be decreased when combined with Carbomycin. | Vet Approved |
| Carfilzomib | The serum concentration of Carfilzomib can be increased when it is combined with Nitrendipine. | Approved |
| Caroxazone | Caroxazone may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Carteolol | Carteolol may increase the hypotensive activities of Nitrendipine. | Approved |
| Carvedilol | Nitrendipine may increase the hypotensive activities of Carvedilol. | Approved, Investigational |
| Caspofungin | The risk or severity of adverse effects can be increased when Caspofungin is combined with Nitrendipine. | Approved |
| Celiprolol | Nitrendipine may increase the hypotensive activities of Celiprolol. | Approved, Investigational |
| Ceritinib | The serum concentration of Nitrendipine can be increased when it is combined with Ceritinib. | Approved |
| Cerivastatin | The serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine. | Withdrawn |
| Cerulenin | The risk or severity of adverse effects can be increased when Cerulenin is combined with Nitrendipine. | Approved |
| Chlorothiazide | Chlorothiazide may increase the hypotensive activities of Nitrendipine. | Approved, Vet Approved |
| Chloroxine | The risk or severity of adverse effects can be increased when Chloroxine is combined with Nitrendipine. | Approved |
| Chlorpromazine | The serum concentration of Chlorpromazine can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Chlorthalidone | Chlorthalidone may increase the hypotensive activities of Nitrendipine. | Approved |
| Ciclopirox | The risk or severity of adverse effects can be increased when Ciclopirox is combined with Nitrendipine. | Approved, Investigational |
| Cilazapril | Nitrendipine may increase the hypotensive activities of Cilazapril. | Approved |
| Cilnidipine | The risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine. | Approved |
| Cimetidine | The serum concentration of Nitrendipine can be increased when it is combined with Cimetidine. | Approved |
| Ciprofloxacin | The serum concentration of Ciprofloxacin can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Cisplatin | The serum concentration of Cisplatin can be increased when it is combined with Nitrendipine. | Approved |
| Citalopram | The serum concentration of Citalopram can be increased when it is combined with Nitrendipine. | Approved |
| Clarithromycin | The metabolism of Nitrendipine can be decreased when combined with Clarithromycin. | Approved |
| Clemastine | The metabolism of Nitrendipine can be decreased when combined with Clemastine. | Approved |
| Clevidipine | The risk or severity of adverse effects can be increased when Clevidipine is combined with Nitrendipine. | Approved |
| Clobazam | The serum concentration of Clobazam can be increased when it is combined with Nitrendipine. | Approved, Illicit |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine. | Approved, Investigational |
| Clomifene | The serum concentration of Clomifene can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Clomipramine | The risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine. | Approved, Vet Approved |
| Clonidine | The serum concentration of Clonidine can be increased when it is combined with Nitrendipine. | Approved |
| Clopidogrel | The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine. | Approved, Nutraceutical |
| Clotrimazole | The risk or severity of adverse effects can be increased when Clotrimazole is combined with Nitrendipine. | Approved, Vet Approved |
| Clozapine | The serum concentration of Clozapine can be increased when it is combined with Nitrendipine. | Approved |
| Cobicistat | The metabolism of Nitrendipine can be decreased when combined with Cobicistat. | Approved |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Nitrendipine. | Approved |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Nitrendipine. | Approved |
| Conivaptan | The serum concentration of Nitrendipine can be increased when it is combined with Conivaptan. | Approved, Investigational |
| Conjugated estrogens | The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nitrendipine. | Approved |
| Cordycepin | The risk or severity of adverse effects can be increased when Cordycepin is combined with Nitrendipine. | Investigational |
| Crizotinib | The metabolism of Nitrendipine can be decreased when combined with Crizotinib. | Approved |
| Cryptenamine | Cryptenamine may increase the hypotensive activities of Nitrendipine. | Approved |
| Cyclosporine | The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nitrendipine. | Approved, Investigational, Vet Approved |
| Cyclothiazide | Cyclothiazide may increase the hypotensive activities of Nitrendipine. | Approved |
| Dabigatran etexilate | The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine. | Approved |
| Dabrafenib | The serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib. | Approved |
| Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Nitrendipine. | Approved |
| Dapagliflozin | The serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine. | Approved |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Nitrendipine. | Investigational |
| Darunavir | The metabolism of Nitrendipine can be decreased when combined with Darunavir. | Approved |
| Dasatinib | The serum concentration of Nitrendipine can be increased when it is combined with Dasatinib. | Approved, Investigational |
| Daunorubicin | The serum concentration of Daunorubicin can be increased when it is combined with Nitrendipine. | Approved |
| Debrisoquin | The serum concentration of Debrisoquin can be increased when it is combined with Nitrendipine. | Approved |
| Deferasirox | The serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox. | Approved, Investigational |
| Delavirdine | The metabolism of Nitrendipine can be decreased when combined with Delavirdine. | Approved |
| Deserpidine | Nitrendipine may increase the hypotensive activities of Deserpidine. | Approved |
| Desflurane | The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine. | Approved |
| Dexamethasone | The serum concentration of Nitrendipine can be decreased when it is combined with Dexamethasone. | Approved, Investigational, Vet Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitrendipine. | Approved, Vet Approved |
| Diazepam | The serum concentration of Diazepam can be increased when it is combined with Nitrendipine. | Approved, Illicit, Vet Approved |
| Diazoxide | Diazoxide may increase the hypotensive activities of Nitrendipine. | Approved |
| Diclofenamide | The risk or severity of adverse effects can be increased when Diclofenamide is combined with Nitrendipine. | Approved |
| Diethylstilbestrol | The serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrendipine. | Approved |
| Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Nitrendipine. | Approved |
| Digoxin | The serum concentration of Digoxin can be increased when it is combined with Nitrendipine. | Approved |
| Dihydralazine | Nitrendipine may increase the hypotensive activities of Dihydralazine. | Investigational |
| Dihydroergotamine | The metabolism of Nitrendipine can be decreased when combined with Dihydroergotamine. | Approved |
| Dihydrotestosterone | The serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrendipine. | Illicit |
| Diltiazem | The metabolism of Nitrendipine can be decreased when combined with Diltiazem. | Approved |
| Dinutuximab | The risk or severity of adverse effects can be increased when Dinutuximab is combined with Nitrendipine. | Approved |
| Dipyridamole | The serum concentration of Dipyridamole can be increased when it is combined with Nitrendipine. | Approved |
| Docetaxel | The serum concentration of Docetaxel can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Domperidone | The serum concentration of Domperidone can be increased when it is combined with Nitrendipine. | Approved, Investigational, Vet Approved |
| Dorzolamide | Dorzolamide may increase the hypotensive activities of Nitrendipine. | Approved |
| Doxazosin | Doxazosin may increase the hypotensive activities of Nitrendipine. | Approved |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Doxycycline | The metabolism of Nitrendipine can be decreased when combined with Doxycycline. | Approved, Investigational, Vet Approved |
| Dronedarone | The metabolism of Nitrendipine can be decreased when combined with Dronedarone. | Approved |
| Duloxetine | Nitrendipine may increase the orthostatic hypotensive activities of Duloxetine. | Approved |
| Econazole | The risk or severity of adverse effects can be increased when Econazole is combined with Nitrendipine. | Approved |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Nitrendipine. | Approved |
| Efavirenz | The serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz. | Approved, Investigational |
| Efinaconazole | The risk or severity of adverse effects can be increased when Efinaconazole is combined with Nitrendipine. | Approved |
| Efonidipine | Nitrendipine may increase the hypotensive activities of Efonidipine. | Approved |
| Eletriptan | The serum concentration of Eletriptan can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Empagliflozin | The risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitrendipine. | Approved |
| Enalapril | Enalapril may increase the hypotensive activities of Nitrendipine. | Approved, Vet Approved |
| Enalaprilat | Nitrendipine may increase the hypotensive activities of Enalaprilat. | Approved |
| Enzalutamide | The serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide. | Approved |
| Epinastine | The serum concentration of Epinastine can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Eplerenone | The risk or severity of adverse effects can be increased when Eplerenone is combined with Nitrendipine. | Approved |
| Epoprostenol | Nitrendipine may increase the hypotensive activities of Epoprostenol. | Approved |
| Eprosartan | Eprosartan may increase the hypotensive activities of Nitrendipine. | Approved |
| Erlotinib | The serum concentration of Erlotinib can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Erythromycin | The metabolism of Nitrendipine can be decreased when combined with Erythromycin. | Approved, Vet Approved |
| Eslicarbazepine acetate | The serum concentration of Nitrendipine can be decreased when it is combined with Eslicarbazepine acetate. | Approved |
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with Nitrendipine. | Approved |
| Estradiol | The serum concentration of Estradiol can be increased when it is combined with Nitrendipine. | Approved, Investigational, Vet Approved |
| Estriol | The serum concentration of Estriol can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Estrone | The serum concentration of Estrone can be increased when it is combined with Nitrendipine. | Approved |
| Etacrynic acid | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nitrendipine. | Approved |
| Ethinyl Estradiol | The serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrendipine. | Approved |
| Etoposide | The serum concentration of Etoposide can be increased when it is combined with Nitrendipine. | Approved |
| Etravirine | The serum concentration of Nitrendipine can be decreased when it is combined with Etravirine. | Approved |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Nitrendipine. | Approved |
| Ezetimibe | The serum concentration of Ezetimibe can be increased when it is combined with Nitrendipine. | Approved |
| Felodipine | Felodipine may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Fenoldopam | Fenoldopam may increase the hypotensive activities of Nitrendipine. | Approved |
| Fesoterodine | The serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine. | Approved |
| Fexofenadine | The serum concentration of Fexofenadine can be increased when it is combined with Nitrendipine. | Approved |
| Fidaxomicin | The serum concentration of Fidaxomicin can be increased when it is combined with Nitrendipine. | Approved |
| Fimasartan | The risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine. | Approved |
| Fluconazole | The serum concentration of Nitrendipine can be increased when it is combined with Fluconazole. | Approved |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Nitrendipine. | Approved |
| Fluticasone furoate | The serum concentration of Fluticasone furoate can be increased when it is combined with Nitrendipine. | Approved |
| Fluvoxamine | The metabolism of Nitrendipine can be decreased when combined with Fluvoxamine. | Approved, Investigational |
| Fosamprenavir | The metabolism of Nitrendipine can be decreased when combined with Fosamprenavir. | Approved |
| Fosaprepitant | The serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant. | Approved |
| Fosinopril | Fosinopril may increase the hypotensive activities of Nitrendipine. | Approved |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with Nitrendipine. | Approved |
| Furazolidone | Furazolidone may increase the hypotensive activities of Nitrendipine. | Approved, Vet Approved |
| Furosemide | The risk or severity of adverse effects can be increased when Furosemide is combined with Nitrendipine. | Approved, Vet Approved |
| Fusidic Acid | The serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid. | Approved |
| Gefitinib | The serum concentration of Gefitinib can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Nitrendipine. | Approved |
| Glyphosate | The risk or severity of adverse effects can be increased when Glyphosate is combined with Nitrendipine. | Experimental |
| Grazoprevir | The serum concentration of Grazoprevir can be increased when it is combined with Nitrendipine. | Approved |
| Grepafloxacin | The serum concentration of Grepafloxacin can be increased when it is combined with Nitrendipine. | Withdrawn |
| Griseofulvin | The risk or severity of adverse effects can be increased when Griseofulvin is combined with Nitrendipine. | Approved, Vet Approved |
| Guanabenz | Guanabenz may increase the hypotensive activities of Nitrendipine. | Approved |
| Guanadrel | Guanadrel may increase the hypotensive activities of Nitrendipine. | Approved |
| Guanethidine | Nitrendipine may increase the hypotensive activities of Guanethidine. | Approved |
| Guanfacine | Guanfacine may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Haloperidol | The serum concentration of Haloperidol can be increased when it is combined with Nitrendipine. | Approved |
| Haloprogin | The risk or severity of adverse effects can be increased when Haloprogin is combined with Nitrendipine. | Approved, Withdrawn |
| Halothane | The risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine. | Approved, Vet Approved |
| Hexamethonium | Nitrendipine may increase the hypotensive activities of Hexamethonium. | Experimental |
| Hexetidine | The risk or severity of adverse effects can be increased when Hexetidine is combined with Nitrendipine. | Approved |
| Hexobarbital | The metabolism of Nitrendipine can be increased when combined with Hexobarbital. | Approved |
| Hydracarbazine | Hydracarbazine may increase the hypotensive activities of Nitrendipine. | Experimental |
| Hydralazine | Nitrendipine may increase the hypotensive activities of Hydralazine. | Approved |
| Hydrochlorothiazide | Hydrochlorothiazide may increase the hypotensive activities of Nitrendipine. | Approved, Vet Approved |
| Hydrocortisone | The serum concentration of Hydrocortisone can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Hydroflumethiazide | Hydroflumethiazide may increase the hypotensive activities of Nitrendipine. | Approved |
| Ibuprofen | The serum concentration of Ibuprofen can be increased when it is combined with Nitrendipine. | Approved |
| Idelalisib | The serum concentration of Nitrendipine can be increased when it is combined with Idelalisib. | Approved |
| Iloprost | Iloprost may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Imatinib | The metabolism of Nitrendipine can be decreased when combined with Imatinib. | Approved |
| Imidapril | The risk or severity of adverse effects can be increased when Imidapril is combined with Nitrendipine. | Investigational |
| Imipramine | The serum concentration of Imipramine can be increased when it is combined with Nitrendipine. | Approved |
| Indacaterol | The serum concentration of Indacaterol can be increased when it is combined with Nitrendipine. | Approved |
| Indapamide | Indapamide may increase the hypotensive activities of Nitrendipine. | Approved |
| Indenolol | Nitrendipine may increase the hypotensive activities of Indenolol. | Withdrawn |
| Indinavir | The metabolism of Nitrendipine can be decreased when combined with Indinavir. | Approved |
| Indomethacin | The serum concentration of Indomethacin can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Indoramin | Nitrendipine may increase the hypotensive activities of Indoramin. | Withdrawn |
| Iproclozide | Iproclozide may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Iproniazid | Iproniazid may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Irbesartan | Irbesartan may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Irinotecan | The serum concentration of Irinotecan can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Isavuconazonium | The metabolism of Nitrendipine can be decreased when combined with Isavuconazonium. | Approved, Investigational |
| Isocarboxazid | Isocarboxazid may increase the hypotensive activities of Nitrendipine. | Approved |
| Isoconazole | The risk or severity of adverse effects can be increased when Isoconazole is combined with Nitrendipine. | Approved |
| Isoflurane | The risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrendipine. | Approved, Vet Approved |
| Isosorbide Dinitrate | The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nitrendipine. | Approved |
| Isosorbide Mononitrate | The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nitrendipine. | Approved |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Nitrendipine. | Approved, Withdrawn |
| Isradipine | The metabolism of Nitrendipine can be decreased when combined with Isradipine. | Approved |
| Itraconazole | The metabolism of Nitrendipine can be decreased when combined with Itraconazole. | Approved, Investigational |
| Ivacaftor | The serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor. | Approved |
| Ivermectin | The serum concentration of Ivermectin can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Josamycin | The metabolism of Nitrendipine can be decreased when combined with Josamycin. | Approved |
| Ketanserin | Nitrendipine may increase the hypotensive activities of Ketanserin. | Investigational |
| Ketazolam | The serum concentration of Ketazolam can be increased when it is combined with Nitrendipine. | Approved |
| Ketoconazole | The metabolism of Nitrendipine can be decreased when combined with Ketoconazole. | Approved, Investigational |
| Kitasamycin | The metabolism of Nitrendipine can be decreased when combined with Kitasamycin. | Experimental |
| Labetalol | Labetalol may increase the hypotensive activities of Nitrendipine. | Approved |
| Lacidipine | Nitrendipine may increase the hypotensive activities of Lacidipine. | Approved |
| Lamivudine | The serum concentration of Lamivudine can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Lamotrigine | The serum concentration of Lamotrigine can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Lansoprazole | The serum concentration of Lansoprazole can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Latanoprost | Latanoprost may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine. | Approved |
| Lenalidomide | The serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine. | Approved |
| Lenvatinib | The serum concentration of Lenvatinib can be increased when it is combined with Nitrendipine. | Approved |
| Lercanidipine | Lercanidipine may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Levetiracetam | The serum concentration of Levetiracetam can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Levobunolol | The risk or severity of adverse effects can be increased when Levobunolol is combined with Nitrendipine. | Approved |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrendipine. | Approved |
| Levodopa | Nitrendipine may increase the orthostatic hypotensive activities of Levodopa. | Approved |
| Levofloxacin | The serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Levomilnacipran | The serum concentration of Levomilnacipran can be increased when it is combined with Nitrendipine. | Approved |
| Levosimendan | The risk or severity of adverse effects can be increased when Levosimendan is combined with Nitrendipine. | Approved, Investigational |
| Linagliptin | The serum concentration of Linagliptin can be increased when it is combined with Nitrendipine. | Approved |
| Lisinopril | Lisinopril may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Lofexidine | Nitrendipine may increase the hypotensive activities of Lofexidine. | Approved, Investigational |
| Loperamide | The serum concentration of Loperamide can be increased when it is combined with Nitrendipine. | Approved |
| Lopinavir | The metabolism of Nitrendipine can be decreased when combined with Lopinavir. | Approved |
| Losartan | The serum concentration of Losartan can be increased when it is combined with Nitrendipine. | Approved |
| Lovastatin | The metabolism of Nitrendipine can be decreased when combined with Lovastatin. | Approved, Investigational |
| Luliconazole | The serum concentration of Nitrendipine can be increased when it is combined with Luliconazole. | Approved |
| Lumacaftor | The metabolism of Nitrendipine can be increased when combined with Lumacaftor. | Approved |
| Macitentan | Nitrendipine may increase the hypotensive activities of Macitentan. | Approved |
| Magnesium Hydroxide | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium hydroxide. | Approved |
| Magnesium oxide | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide. | Approved |
| Magnesium salicylate | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate. | Approved |
| Magnesium Sulfate | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Sulfate. | Approved, Vet Approved |
| Manidipine | Nitrendipine may increase the hypotensive activities of Manidipine. | Approved |
| Mannitol | The serum concentration of Mannitol can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Mebanazine | Mebanazine may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Mecamylamine | Mecamylamine may increase the hypotensive activities of Nitrendipine. | Approved |
| Methazolamide | The risk or severity of adverse effects can be increased when Methazolamide is combined with Nitrendipine. | Approved |
| Methohexital | The metabolism of Nitrendipine can be increased when combined with Methohexital. | Approved |
| Methotrexate | The serum concentration of Methotrexate can be increased when it is combined with Nitrendipine. | Approved |
| Methyclothiazide | The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitrendipine. | Approved |
| Methyldopa | Methyldopa may increase the hypotensive activities of Nitrendipine. | Approved |
| Methylene blue | Methylene blue may increase the hypotensive activities of Nitrendipine. | Investigational |
| Methylphenidate | Methylphenidate may decrease the antihypertensive activities of Nitrendipine. | Approved, Investigational |
| Methylphenobarbital | The metabolism of Nitrendipine can be increased when combined with Methylphenobarbital. | Approved |
| Methylprednisolone | The serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Metipranolol | Nitrendipine may increase the hypotensive activities of Metipranolol. | Approved |
| Metolazone | Metolazone may increase the hypotensive activities of Nitrendipine. | Approved |
| Metoprolol | The serum concentration of Metoprolol can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Metyrosine | Nitrendipine may increase the hypotensive activities of Metyrosine. | Approved |
| Mevastatin | The risk or severity of adverse effects can be increased when Mevastatin is combined with Nitrendipine. | Experimental |
| Mibefradil | Nitrendipine may increase the hypotensive activities of Mibefradil. | Withdrawn |
| Micafungin | The risk or severity of adverse effects can be increased when Micafungin is combined with Nitrendipine. | Approved, Investigational |
| Miconazole | The risk or severity of adverse effects can be increased when Miconazole is combined with Nitrendipine. | Approved, Investigational, Vet Approved |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Nitrendipine. | Approved, Illicit |
| Mifepristone | The serum concentration of Nitrendipine can be increased when it is combined with Mifepristone. | Approved, Investigational |
| Miltefosine | The risk or severity of adverse effects can be increased when Miltefosine is combined with Nitrendipine. | Approved |
| Minaprine | Minaprine may increase the hypotensive activities of Nitrendipine. | Approved |
| Minoxidil | Minoxidil may increase the hypotensive activities of Nitrendipine. | Approved |
| Mirabegron | The serum concentration of Mirabegron can be increased when it is combined with Nitrendipine. | Approved |
| Mitotane | The serum concentration of Nitrendipine can be decreased when it is combined with Mitotane. | Approved |
| Mitoxantrone | The serum concentration of Mitoxantrone can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Mivacurium | Nitrendipine may increase the neuromuscular blocking activities of Mivacurium. | Approved |
| Moclobemide | Moclobemide may increase the hypotensive activities of Nitrendipine. | Approved |
| Modafinil | The serum concentration of Nitrendipine can be decreased when it is combined with Modafinil. | Approved, Investigational |
| Moexipril | Moexipril may increase the hypotensive activities of Nitrendipine. | Approved |
| Molsidomine | Molsidomine may increase the hypotensive activities of Nitrendipine. | Approved |
| Monensin | The risk or severity of adverse effects can be increased when Monensin is combined with Nitrendipine. | Vet Approved |
| Morphine | The serum concentration of Morphine can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Moxonidine | Nitrendipine may increase the hypotensive activities of Moxonidine. | Approved |
| Mycophenolate mofetil | The serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Myxothiazol | The risk or severity of adverse effects can be increased when Myxothiazol is combined with Nitrendipine. | Experimental |
| Nabilone | The risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine. | Approved, Investigational |
| Nadolol | The serum concentration of Nadolol can be increased when it is combined with Nitrendipine. | Approved |
| Nafcillin | The metabolism of Nitrendipine can be increased when combined with Nafcillin. | Approved |
| Naftifine | The risk or severity of adverse effects can be increased when Naftifine is combined with Nitrendipine. | Approved |
| Naftopidil | Nitrendipine may increase the hypotensive activities of Naftopidil. | Investigational |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Nitrendipine. | Approved |
| Naloxone | The serum concentration of Naloxone can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Natamycin | The risk or severity of adverse effects can be increased when Natamycin is combined with Nitrendipine. | Approved |
| Nebivolol | Nitrendipine may increase the hypotensive activities of Nebivolol. | Approved, Investigational |
| Nefazodone | The metabolism of Nitrendipine can be decreased when combined with Nefazodone. | Approved, Withdrawn |
| Nelfinavir | The metabolism of Nitrendipine can be decreased when combined with Nelfinavir. | Approved |
| Nesiritide | The risk or severity of adverse effects can be increased when Nesiritide is combined with Nitrendipine. | Approved, Investigational |
| Netupitant | The serum concentration of Nitrendipine can be increased when it is combined with Netupitant. | Approved |
| Nevirapine | The metabolism of Nitrendipine can be increased when combined with Nevirapine. | Approved |
| Nialamide | Nialamide may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Nicardipine | The serum concentration of Nicardipine can be increased when it is combined with Nitrendipine. | Approved |
| Nicorandil | Nicorandil may increase the hypotensive activities of Nitrendipine. | Approved |
| Nifedipine | The serum concentration of Nifedipine can be increased when it is combined with Nitrendipine. | Approved |
| Niguldipine | Nitrendipine may increase the hypotensive activities of Niguldipine. | Experimental |
| Nilotinib | The metabolism of Nitrendipine can be decreased when combined with Nilotinib. | Approved, Investigational |
| Nilvadipine | Nitrendipine may increase the hypotensive activities of Nilvadipine. | Approved |
| Nimodipine | Nimodipine may increase the hypotensive activities of Nitrendipine. | Approved |
| Nintedanib | The serum concentration of Nintedanib can be increased when it is combined with Nitrendipine. | Approved |
| Nisoldipine | Nisoldipine may increase the hypotensive activities of Nitrendipine. | Approved |
| Nitric Oxide | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide. | Approved |
| Nitroglycerin | The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nitrendipine. | Approved, Investigational |
| Nitroprusside | Nitrendipine may increase the hypotensive activities of Nitroprusside. | Approved |
| Nitroxoline | The risk or severity of adverse effects can be increased when Nitroxoline is combined with Nitrendipine. | Approved |
| Nizatidine | The serum concentration of Nizatidine can be increased when it is combined with Nitrendipine. | Approved |
| Nystatin | The risk or severity of adverse effects can be increased when Nystatin is combined with Nitrendipine. | Approved, Vet Approved |
| Obinutuzumab | Nitrendipine may increase the hypotensive activities of Obinutuzumab. | Approved |
| Octamoxin | Octamoxin may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Olanzapine | The serum concentration of Olanzapine can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Olaparib | The metabolism of Nitrendipine can be decreased when combined with Olaparib. | Approved |
| Oleandomycin | The metabolism of Nitrendipine can be decreased when combined with Oleandomycin. | Vet Approved |
| Olmesartan | Olmesartan may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Omapatrilat | Omapatrilat may increase the hypotensive activities of Nitrendipine. | Investigational |
| Ombitasvir | The serum concentration of Ombitasvir can be increased when it is combined with Nitrendipine. | Approved |
| Osimertinib | The serum concentration of Nitrendipine can be increased when it is combined with Osimertinib. | Approved |
| Oxiconazole | The risk or severity of adverse effects can be increased when Oxiconazole is combined with Nitrendipine. | Approved |
| Oxprenolol | Nitrendipine may increase the hypotensive activities of Oxprenolol. | Approved |
| Paclitaxel | The serum concentration of Paclitaxel can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| pafuramidine | The risk or severity of adverse effects can be increased when pafuramidine is combined with Nitrendipine. | Investigational |
| Palbociclib | The serum concentration of Nitrendipine can be increased when it is combined with Palbociclib. | Approved |
| Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Papaverine | The risk or severity of adverse effects can be increased when Papaverine is combined with Nitrendipine. | Approved |
| Pargyline | Pargyline may increase the hypotensive activities of Nitrendipine. | Approved |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Nitrendipine. | Approved |
| Penbutolol | Nitrendipine may increase the hypotensive activities of Penbutolol. | Approved, Investigational |
| Pentamidine | The risk or severity of adverse effects can be increased when Pentamidine is combined with Nitrendipine. | Approved |
| Pentobarbital | The metabolism of Nitrendipine can be increased when combined with Pentobarbital. | Approved, Vet Approved |
| Pentolinium | Nitrendipine may increase the hypotensive activities of Pentolinium. | Approved |
| Pentoxifylline | Pentoxifylline may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Perindopril | Perindopril may increase the hypotensive activities of Nitrendipine. | Approved |
| Phenelzine | Phenelzine may increase the hypotensive activities of Nitrendipine. | Approved |
| Pheniprazine | Pheniprazine may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Phenobarbital | The metabolism of Nitrendipine can be increased when combined with Phenobarbital. | Approved |
| Phenoxybenzamine | Phenoxybenzamine may increase the hypotensive activities of Nitrendipine. | Approved |
| Phenoxypropazine | Phenoxypropazine may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Phentolamine | Phentolamine may increase the hypotensive activities of Nitrendipine. | Approved |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Pinacidil | Nitrendipine may increase the hypotensive activities of Pinacidil. | Withdrawn |
| Pindolol | Pindolol may increase the hypotensive activities of Nitrendipine. | Approved |
| Pipamperone | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone. | Approved |
| Pirlindole | Pirlindole may increase the hypotensive activities of Nitrendipine. | Approved |
| Pitavastatin | The serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine. | Approved |
| Pivhydrazine | Pivhydrazine may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Polythiazide | Nitrendipine may increase the hypotensive activities of Polythiazide. | Approved |
| Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Nitrendipine. | Approved |
| Ponatinib | The serum concentration of Ponatinib can be increased when it is combined with Nitrendipine. | Approved |
| Posaconazole | The metabolism of Nitrendipine can be decreased when combined with Posaconazole. | Approved, Investigational, Vet Approved |
| Pramipexole | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole. | Approved, Investigational |
| Pravastatin | The serum concentration of Pravastatin can be increased when it is combined with Nitrendipine. | Approved |
| Prazosin | The serum concentration of Prazosin can be increased when it is combined with Nitrendipine. | Approved |
| Prednisolone | The serum concentration of Prednisolone can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Prednisone | The serum concentration of Prednisone can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Primidone | The metabolism of Nitrendipine can be increased when combined with Primidone. | Approved, Vet Approved |
| Progesterone | The serum concentration of Progesterone can be increased when it is combined with Nitrendipine. | Approved, Vet Approved |
| Propofol | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol. | Approved, Investigational, Vet Approved |
| Propranolol | The serum concentration of Propranolol can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Nitrendipine. | Approved |
| Quetiapine | The serum concentration of Quetiapine can be increased when it is combined with Nitrendipine. | Approved |
| Quinapril | Quinapril may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Quinidine | The serum concentration of Quinidine can be increased when it is combined with Nitrendipine. | Approved |
| Quinine | Quinine may increase the hypotensive activities of Nitrendipine. | Approved |
| Radicicol | The risk or severity of adverse effects can be increased when Radicicol is combined with Nitrendipine. | Experimental |
| Ramipril | Ramipril may increase the hypotensive activities of Nitrendipine. | Approved |
| Ranitidine | The serum concentration of Ranitidine can be increased when it is combined with Nitrendipine. | Approved |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Rapacuronium | Nitrendipine may increase the neuromuscular blocking activities of Rapacuronium. | Withdrawn |
| Rasagiline | Rasagiline may increase the hypotensive activities of Nitrendipine. | Approved |
| Remifentanil | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil. | Approved |
| Remikiren | Remikiren may increase the hypotensive activities of Nitrendipine. | Approved |
| Rescinnamine | Nitrendipine may increase the hypotensive activities of Rescinnamine. | Approved |
| Reserpine | The serum concentration of Reserpine can be increased when it is combined with Nitrendipine. | Approved |
| Rifabutin | The metabolism of Nitrendipine can be increased when combined with Rifabutin. | Approved |
| Rifampicin | The metabolism of Nitrendipine can be increased when combined with Rifampicin. | Approved |
| Rifapentine | The metabolism of Nitrendipine can be increased when combined with Rifapentine. | Approved |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Rilmenidine | Nitrendipine may increase the hypotensive activities of Rilmenidine. | Investigational |
| Riociguat | Nitrendipine may increase the hypotensive activities of Riociguat. | Approved |
| Risperidone | Nitrendipine may increase the hypotensive activities of Risperidone. | Approved, Investigational |
| Ritonavir | The metabolism of Nitrendipine can be decreased when combined with Ritonavir. | Approved, Investigational |
| Rituximab | Nitrendipine may increase the hypotensive activities of Rituximab. | Approved |
| Rivaroxaban | The serum concentration of Rivaroxaban can be increased when it is combined with Nitrendipine. | Approved |
| Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Ropinirole | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine. | Approved |
| Rotigotine | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine. | Approved |
| Sacubitril | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sacubitril. | Approved |
| Safrazine | Safrazine may increase the hypotensive activities of Nitrendipine. | Withdrawn |
| Salicylhydroxamic Acid | The risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nitrendipine. | Experimental |
| Salicylic acid | The risk or severity of adverse effects can be increased when Salicylic acid is combined with Nitrendipine. | Approved, Vet Approved |
| Saprisartan | Nitrendipine may increase the hypotensive activities of Saprisartan. | Experimental |
| Saquinavir | The metabolism of Nitrendipine can be decreased when combined with Saquinavir. | Approved, Investigational |
| Secobarbital | The metabolism of Nitrendipine can be increased when combined with Secobarbital. | Approved, Vet Approved |
| Selegiline | Selegiline may increase the hypotensive activities of Nitrendipine. | Approved, Investigational, Vet Approved |
| Selexipag | The serum concentration of Selexipag can be increased when it is combined with Nitrendipine. | Approved |
| Sertaconazole | The risk or severity of adverse effects can be increased when Sertaconazole is combined with Nitrendipine. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane. | Approved, Vet Approved |
| Sildenafil | Sildenafil may increase the antihypertensive activities of Nitrendipine. | Approved, Investigational |
| Silodosin | The serum concentration of Silodosin can be increased when it is combined with Nitrendipine. | Approved |
| Siltuximab | The serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab. | Approved |
| Simeprevir | The serum concentration of Nitrendipine can be increased when it is combined with Simeprevir. | Approved |
| Sinefungin | The risk or severity of adverse effects can be increased when Sinefungin is combined with Nitrendipine. | Experimental |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Nitrendipine. | Approved, Investigational |
| Sitagliptin | The serum concentration of Sitagliptin can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Sitaxentan | Nitrendipine may increase the hypotensive activities of Sitaxentan. | Approved, Investigational, Withdrawn |
| Sodium Nitrite | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sodium Nitrite. | Approved |
| Sofosbuvir | The serum concentration of Sofosbuvir can be increased when it is combined with Nitrendipine. | Approved |
| Solithromycin | The metabolism of Nitrendipine can be decreased when combined with Solithromycin. | Investigational |
| Sorafenib | The serum concentration of Sorafenib can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with Nitrendipine. | Approved |
| Sparfloxacin | The serum concentration of Sparfloxacin can be increased when it is combined with Nitrendipine. | Approved |
| Sphingosine | The serum concentration of Sphingosine can be increased when it is combined with Nitrendipine. | Experimental |
| Spirapril | Nitrendipine may increase the hypotensive activities of Spirapril. | Approved |
| Spironolactone | The risk or severity of adverse effects can be increased when Spironolactone is combined with Nitrendipine. | Approved |
| St. John's Wort | The serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort. | Nutraceutical |
| Stiripentol | The serum concentration of Nitrendipine can be increased when it is combined with Stiripentol. | Approved |
| Streptokinase | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil. | Approved, Investigational |
| Sulconazole | The risk or severity of adverse effects can be increased when Sulconazole is combined with Nitrendipine. | Approved |
| Sulfisoxazole | The metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole. | Approved, Vet Approved |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Tadalafil | Tadalafil may increase the antihypertensive activities of Nitrendipine. | Approved, Investigational |
| Tamoxifen | The serum concentration of Tamoxifen can be increased when it is combined with Nitrendipine. | Approved |
| Tamsulosin | Tamsulosin may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Taurocholic Acid | The serum concentration of Taurocholic Acid can be increased when it is combined with Nitrendipine. | Experimental |
| Tavaborole | The risk or severity of adverse effects can be increased when Tavaborole is combined with Nitrendipine. | Approved |
| Technetium Tc-99m sestamibi | The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nitrendipine. | Approved |
| Telaprevir | The metabolism of Nitrendipine can be decreased when combined with Telaprevir. | Withdrawn |
| Telithromycin | The metabolism of Nitrendipine can be decreased when combined with Telithromycin. | Approved |
| Telmisartan | Telmisartan may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Temocapril | Nitrendipine may increase the hypotensive activities of Temocapril. | Experimental, Investigational |
| Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine. | Approved |
| Terazosin | Terazosin may increase the hypotensive activities of Nitrendipine. | Approved |
| Terbinafine | The risk or severity of adverse effects can be increased when Terbinafine is combined with Nitrendipine. | Approved, Investigational, Vet Approved |
| Terconazole | The risk or severity of adverse effects can be increased when Terconazole is combined with Nitrendipine. | Approved |
| Terlipressin | Nitrendipine may increase the hypotensive activities of Terlipressin. | Approved, Investigational |
| Thalidomide | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide. | Approved, Investigational, Withdrawn |
| Thiamylal | The metabolism of Nitrendipine can be increased when combined with Thiamylal. | Approved, Vet Approved |
| Thiopental | The metabolism of Nitrendipine can be increased when combined with Thiopental. | Approved, Vet Approved |
| Thioridazine | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thioridazine. | Withdrawn |
| Thymol | The risk or severity of adverse effects can be increased when Thymol is combined with Nitrendipine. | Approved |
| Tibolone | Nitrendipine may increase the hypotensive activities of Tibolone. | Approved |
| Ticagrelor | The serum concentration of Ticagrelor can be increased when it is combined with Nitrendipine. | Approved |
| Ticlopidine | The metabolism of Nitrendipine can be decreased when combined with Ticlopidine. | Approved |
| Ticrynafen | Nitrendipine may increase the hypotensive activities of Ticrynafen. | Withdrawn |
| Timolol | The serum concentration of Timolol can be increased when it is combined with Nitrendipine. | Approved |
| Tioconazole | The risk or severity of adverse effects can be increased when Tioconazole is combined with Nitrendipine. | Approved |
| Tizanidine | The risk or severity of adverse effects can be increased when Tizanidine is combined with Nitrendipine. | Approved |
| Tocilizumab | The serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab. | Approved |
| Tolazoline | Tolazoline may increase the hypotensive activities of Nitrendipine. | Approved, Vet Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone. | Approved, Withdrawn |
| Tolnaftate | The risk or severity of adverse effects can be increased when Tolnaftate is combined with Nitrendipine. | Approved, Vet Approved |
| Toloxatone | Toloxatone may increase the hypotensive activities of Nitrendipine. | Approved |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Nitrendipine. | Approved |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Torasemide | Torasemide may increase the hypotensive activities of Nitrendipine. | Approved |
| Toremifene | The serum concentration of Toremifene can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Trandolapril | Trandolapril may increase the hypotensive activities of Nitrendipine. | Approved |
| Trans-2-Phenylcyclopropylamine | Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitrendipine. | Experimental |
| Tranylcypromine | Tranylcypromine may increase the hypotensive activities of Nitrendipine. | Approved |
| Trastuzumab emtansine | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Nitrendipine. | Approved |
| Travoprost | Travoprost may increase the hypotensive activities of Nitrendipine. | Approved |
| Treprostinil | Treprostinil may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Tretinoin | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tretinoin. | Approved, Investigational, Nutraceutical |
| Triamterene | The risk or severity of adverse effects can be increased when Triamterene is combined with Nitrendipine. | Approved |
| Trichlormethiazide | Trichlormethiazide may increase the hypotensive activities of Nitrendipine. | Approved, Vet Approved |
| Trimazosin | Nitrendipine may increase the hypotensive activities of Trimazosin. | Experimental |
| Trimethaphan | Nitrendipine may increase the hypotensive activities of Trimethaphan. | Approved |
| Trimetrexate | The risk or severity of adverse effects can be increased when Trimetrexate is combined with Nitrendipine. | Approved, Investigational |
| Tylosin | The metabolism of Nitrendipine can be decreased when combined with Tylosin. | Vet Approved |
| Udenafil | Udenafil may increase the antihypertensive activities of Nitrendipine. | Approved, Investigational |
| Ulipristal | The serum concentration of Ulipristal can be increased when it is combined with Nitrendipine. | Approved |
| Umeclidinium | The serum concentration of Umeclidinium can be increased when it is combined with Nitrendipine. | Approved |
| Unoprostone | Nitrendipine may increase the hypotensive activities of Unoprostone. | Approved |
| Ursodeoxycholic acid | Ursodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved, Investigational |
| Valsartan | Valsartan may increase the hypotensive activities of Nitrendipine. | Approved, Investigational |
| Vardenafil | Vardenafil may increase the antihypertensive activities of Nitrendipine. | Approved |
| Vecuronium | The serum concentration of Vecuronium can be increased when it is combined with Nitrendipine. | Approved |
| Venetoclax | The serum concentration of Venetoclax can be increased when it is combined with Nitrendipine. | Approved |
| Venlafaxine | The metabolism of Nitrendipine can be decreased when combined with Venlafaxine. | Approved |
| Verapamil | The metabolism of Nitrendipine can be decreased when combined with Verapamil. | Approved |
| Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Nitrendipine. | Approved |
| Vincristine | The serum concentration of Vincristine can be increased when it is combined with Nitrendipine. | Approved, Investigational |
| Vinpocetine | Nitrendipine may increase the hypotensive activities of Vinpocetine. | Investigational |
| Vismodegib | The serum concentration of Vismodegib can be increased when it is combined with Nitrendipine. | Approved |
| Voriconazole | The metabolism of Nitrendipine can be decreased when combined with Voriconazole. | Approved, Investigational |
| Xylometazoline | Nitrendipine may increase the hypotensive activities of Xylometazoline. | Approved |
| Yohimbine | Yohimbine may decrease the antihypertensive activities of Nitrendipine. | Approved, Vet Approved |
| Zidovudine | The serum concentration of Zidovudine can be increased when it is combined with Nitrendipine. | Approved |
| Ziprasidone | The metabolism of Nitrendipine can be decreased when combined with Ziprasidone. | Approved |
